Senescence marker, method for evaluating senescence inhibitor, and cancer inhibitor

Abstract

The present invention aims to elucidate a miRNA involved in cellular senescence and to provide a method of use thereof. The senescence marker of the present invention comprises a gene transcript of miR-22. Further, the method for evaluating a senescence inhibitor of the present invention comprises the step of measuring the expression level of a gene transcript of miR-22 in a sample in the presence of a test compound and in the absence of the test compound; and the step of comparing the expression level of the gene transcript of miR-22 in the sample in the presence of the test compound with the expression level of the gene transcript of miR-22 in the sample in the absence of the test compound. Further, the cancer inhibitor of the present invention comprises as an effective component a gene transcript of miR-22, which cancer inhibitor promotes cellular senescence and inhibits invasion and/or metastasis of cancer.

1 . A senescence marker comprising a gene transcript of miR-22. 
     
     
         2 . The senescence marker according to  claim 1 , wherein said gene transcript of miR-22 comprises RNA with the base sequence shown in SEQ ID NO:1, RNA with the base sequence shown in SEQ ID NO:2, and/or RNA with the base sequence shown in SEQ ID NO:3. 
     
     
         3 . The senescence marker according to  claim 1 , wherein said gene transcript of miR-22 comprises Pre-hsa-miR-22 and/or double-stranded hsa-miR-22. 
     
     
         4 . A method for evaluating a senescence inhibitor, said method comprising:
 the step of measuring the expression level of a gene transcript of miR-22 in a sample in the presence of a test compound and in the absence of the test compound; and   the step of comparing the expression level of said gene transcript of miR-22 in said sample in the presence of said test compound with the expression level of said gene transcript of miR-22 in said sample in the absence of said test compound.   
     
     
         5 . The method for evaluating a senescence inhibitor according to  claim 4 , wherein said gene transcript of miR-22 comprises RNA with the base sequence shown in SEQ ID NO:1, RNA with the base sequence shown in SEQ ID NO:2, and/or RNA with the base sequence shown in SEQ ID NO:3. 
     
     
         6 . The method for evaluating a senescence inhibitor according to  claim 4 , wherein said sample is a sample derived from a mammalian individual. 
     
     
         7 . The method for evaluating a senescence inhibitor according to  claim 4 , wherein said sample is a human fibroblast(s). 
     
     
         8 . A promoter of cellular senescence for cancer comprising as an effective component a gene transcript of miR-22, which promoter of cellular senescence for cancer promotes cellular senescence and inhibits invasion and/or metastasis of cancer. 
     
     
         9 . The promoter of cellular senescence for cancer according to  claim 8 , wherein said gene transcript of miR-22 comprises RNA with the base sequence shown in SEQ ID NO:1, RNA with the base sequence shown in SEQ ID NO:2, and/or RNA with the base sequence shown in SEQ ID NO:3. 
     
     
         10 . The promoter of cellular senescence for cancer according to  claim 8 , wherein said gene transcript of miR-22 comprises Pre-hsa-miR-22 and/or double-stranded hsa-miR-22. 
     
     
         11 . The promoter of cellular senescence for cancer according to  claim 8 , which is a promoter of cellular senescence for gastric cancer, promoter of cellular senescence for uterine cancer, promoter of cellular senescence for pharyngeal cancer, promoter of cellular senescence for breast cancer, promoter of cellular senescence for cervical cancer and/or promoter of cellular senescence for colon cancer. 
     
     
         12 . The promoter of cellular senescence for cancer according to  claim 8 , which is a promoter of cellular senescence for cervical cancer and/or promoter of cellular senescence for breast cancer.